An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Summary

The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.

Timeline

Start

2026-07-15

Primary completion

2027-07-19

Completion

2027-08-19

Drugs

Indications